TTAM Research Institute

What does TTAM Research Institute own?

TTAM owns substantially all of the former 23andMe operating business, including the Personal Genome Service consumer DNA testing line, the 23andMe research services business, and the Lemonaid Health telehealth unit. It acquired these assets from 23andMe Holding Co. in July 2025.

Is TTAM Research Institute publicly traded?

No. TTAM is a nonprofit public benefit corporation and has no stock. It cannot be publicly traded, and no equity interests exist for public investors.

Who founded TTAM Research Institute?

Anne Wojcicki, the co-founder and former chief executive of 23andMe, founded and leads TTAM Research Institute. The name derives from the initials of her full name.

Where is TTAM Research Institute headquartered?

The organization is based in California, operating out of the San Francisco Bay Area, where 23andMe was historically headquartered.

How many brands does TTAM own?

Its principal consumer brand is 23andMe, plus the Lemonaid Health telehealth service and the 23andMe research business. The portfolio is small and concentrated in consumer health.

Who owns TTAM Research Institute?

Nobody owns it in the conventional sense. As a nonprofit public benefit corporation it has no shareholders and is controlled by its board of directors and mission charter. Anne Wojcicki founded the organization and leads it.

What is TTAM's relationship to Regeneron?

Regeneron Pharmaceuticals won the first bankruptcy auction for 23andMe's assets at 256 million dollars but lost the reopened auction when the court allowed TTAM to bid. TTAM ultimately won with a 305 million dollar offer, so Regeneron holds no ownership interest.

TTAM was formed in the first half of 2025 by Anne Wojcicki as 23andMe slid toward insolvency. The public company had filed for Chapter 11 protection on March 23, 2025 in the US Bankruptcy Court for the Eastern District of Missouri, after years of declining kit sales, the reputational damage of a 2023 data breach, and failed attempts to take the business private.

A first bankruptcy auction in May 2025 ended with Regeneron Pharmaceuticals as the winning bidder at 256 million dollars. Wojcicki challenged the process, arguing her nonprofit had been improperly excluded, and the court reopened the auction. In the final round in June 2025, TTAM submitted a winning bid of 305 million dollars for substantially all of 23andMe's assets, including the Personal Genome Service, Research Services, and the Lemonaid Health telehealth unit.

The sale closed on July 14, 2025. The former public parent, 23andMe Holding Co., was renamed Chrome Holding Co. and moved into liquidation under a plan that became effective December 5, 2025, leaving a plan administration trust to resolve creditor claims. TTAM took over the operating business and continues to run it as a nonprofit research institute.

Since the acquisition TTAM has focused on restoring customer trust and stabilizing the service. It committed to maintaining customer privacy controls, including opt-in choices on research participation, and to operating 23andMe under nonprofit governance rather than commercial shareholder pressure.

The organization's defining ethical commitments are written into the terms of its bankruptcy court purchase. It agreed to honor 23andMe's existing privacy policy, to maintain the ability of customers to choose whether their data is used in research, and to restrict any future transfer of genetic data to an owner that would adopt equivalent protections.

The Consumer Privacy Advisory Board adds a governance layer that did not exist under the public company. Critics of the sale, including several state attorneys general, argued that genetic data should not transfer without fresh opt-in consent; the court disagreed but TTAM adopted the advisory structure in response. How the institute performs against these commitments will determine its credibility.

The formation of TTAM is bound up with the 23andMe bankruptcy and the 2023 data breach that exposed profile information of about 6.9 million users. Several US states objected in bankruptcy court to the sale of genetic data, arguing state genetic privacy laws required renewed customer consent. The court approved the sale to TTAM with privacy conditions attached.

A longer-running debate concerns whether a founder-controlled nonprofit acquiring a failed public company's assets creates conflicts. Wojcicki had attempted to take 23andMe private before the bankruptcy, and some shareholders questioned the sale process. The court-supervised auction resolved the transaction, and the plan administration trust is handling remaining creditor claims through 2026.